This cross-sectional study was approved by the Ethics Committee of the Guilan University of Medical Sciences, Rasht, Iran (
IR.GUMS.REC.1401.034). Participants were selected through a convenience sampling method, and the study’s sample size was calculated as 50 (
22). The participants included health professionals from various fields (pharmacy, nursing, general practice, gynecology, internal medicine, orthopedics, biochemistry, forensic medicine, nuclear medicine, general surgery, dentistry, and physiology) at the Guilan University of Medical Sciences, Rasht, Iran, in 2022, and all consented to participate in the study.
Inclusion criteria required participants to be health professionals from medical and biomedical departments affiliated with the Guilan University of Medical Sciences. Individuals who were not health professionals or did not belong to medical or biomedical fields were excluded from the study. Health professionals who declined to provide informed consent or participate in the training workshop were also excluded. Data collected from participants included gender, age, level of education, academic degree, field of study, employment status, and history of attendance in similar workshops.
The ethical principles workshop (conducted both in-person and virtually) lasted 8 hours and covered the following domains: Medical research laws, international regulations, ethical guidelines on human subjects, and national laws. The status of awareness of ethical principles in clinical trials was assessed before and after the workshop using a self-designed questionnaire consisting of ten questions, each scored from 0 to 10 (one point for each correct answer).
Figure 1 shows the flow diagram of the studied participants.
3.1. Instruments
The questionnaire covers ten key domains of ethical principles in clinical trials: "The necessity of a scientific protocol for conducting clinical trials", "the requirement for obtaining informed consent", "the standardization of testing procedures for all interventions", "considerations for including female participants", "age restrictions for healthy volunteers in radiation-based trials", "the regulatory process for clinical studies involving unapproved drugs", "the acceptability of placebo use when standard treatments exist", "conditions under which placebo use is permissible in clinical trials", "the responsibility for compensating participants for study-related injuries", and "the nature of compensation for trial-related injuries, specifically whether it is contingent on proving researcher negligence".
Each question’s content validity ratio (CVR) was calculated based on responses from seven research ethics specialists. Questions with coefficients below 0.7 were eliminated, resulting in the removal of one question. The overall CVR for the ten remaining questions was 0.88. The Content Validity Index (CVI) was assessed regarding relevance, clarity, and acceptability, achieving a CVI score above 0.8, with the overall CVI calculated at 0.931. Subsequently, a pilot study was conducted involving 35 Guilan University of Medical Sciences faculty members to determine the questionnaire’s reliability and validity. The reliability of the questionnaire was evaluated using Cronbach’s alpha, yielding a coefficient of 0.83.
3.2. Statistical Analysis
Data were presented as numbers (percentages) and mean ± standard deviation (SD). The Shapiro-Wilk test was used to assess the normality of the data. To evaluate the differences between variables, paired samples and independent sample t-tests, Kruskal-Wallis, Mann-Whitney U, and ANOVA were performed. Data were analyzed using SPSS version 26, and the significance level was set at < 0.05.